Kezar Life Sciences, Inc. (KZR) Cash from Investing Activities (2017 - 2026)

Kezar Life Sciences has reported Cash from Investing Activities for 10 years, with the latest figure at $1.5 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 88.87% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.2 million (up 8.8% YoY) and the FY2025 annual result came in at $92.5 million, up 14.96% from the prior year.
• Cash from Investing Activities fell to $1.5 million in Q1 2026 per KZR's latest filing, from $51.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $51.6 million in Q4 2025 and troughed at -$59.5 million in Q1 2022.
• A 5-year average of $9.4 million and a median of $13.7 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 8565.65% in 2022, then jumped 774.37% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$8.7 million in 2022, then surged by 421.88% to $27.9 million in 2023, then slipped by 14.83% to $23.7 million in 2024, then soared by 117.37% to $51.6 million in 2025, then plunged by 97.04% to $1.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $1.5 million, $51.6 million, and $15.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.